I'm a bit worried about recommending a share to my clients that's gunning for approval in Russia. No offence, but this is hardly the most stringent market out there.
We can safely say that if they can't win Russia over, then TGA/FDA approval will be a wistful dream.
At least management can take a nice shareholder-sponsored vacation before the Bioeffectives hit the fan.
Strong buy. Short-term price target is $2.50. 12-month price target is $0.50.
